No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACRE240517P7500
- 0.62
- -0.16-20.51%
15min DelayTrading May 14 09:35 ET
0.62High0.62Low
0.62Open0.78Pre Close5 Volume221 Open Interest7.50Strike Price310.00Turnover93.63%IV-0.37%PremiumMay 17, 2024Expiry Date0.73Intrinsic Value100Multiplier3DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.8344Delta0.3973Gamma9.03Leverage Ratio-0.0210Theta-0.0005Rho-7.54Eff Leverage0.0017Vega
Intraday
- 5D
- 1D
News
Ares Commercial Real Estate Corporation (NYSE:ACRE) Q1 2024 Earnings Call Transcript
Ares Commercial Real Est Is Maintained at Market Perform by Keefe, Bruyette & Woods
Ares Commercial Real Est Is Maintained at Market Perform by Keefe, Bruyette & Woods
Express News | Keefe, Bruyette & Woods Maintains Market Perform on Ares Comml Real Est, Lowers Price Target to $7
Ares Comml Real Est Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 4.48% Keefe, Bruyette & Woods $7.5 → $7 Maintains Market Perform 04/10/2024 11.94% Keefe, Bruye
Ares Commercial Real Estate Corp.: Hold Rating Maintained Amidst Financial Uncertainties and Dividend Stability
Q1 2024 Ares Commercial Real Estate Corp Earnings Call
Comments
Despite Ares Commercial Real Estate's declining EPS and share price, market optimism suggests potential investment opportunities. However, 5 warning signs in investment analysis, including 2 significant ones, could be concerning.
Pulling Back 11% This Week, Ares Commercial Real Estate's NYSE:ACRE) Five-year Decline in Earnings May Be Coming Into Investors FocusThe JMP analyst advises a cautious stance on ACRE amid current challenges, insisting on monitoring credit resolutions and new problem credits to gain confidence in future book value per share.
Gainers:
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
18
1
Gainers:
• $National CineMedia(NCMI.US$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor(MX.US$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal(DLO.US$ +13.7% (In reaction to earnings)
• $SiriusPoint(SPNT.US$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air(XAIR.US$ +6.4% (presents positive study update from the at-home LungF...
• $National CineMedia(NCMI.US$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor(MX.US$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal(DLO.US$ +13.7% (In reaction to earnings)
• $SiriusPoint(SPNT.US$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air(XAIR.US$ +6.4% (presents positive study update from the at-home LungF...
14
1
Read more